Boehringer Ingelheim Animal Health Updates Local Veterinarians with New Developments

Boehringer Ingelheim Animal Health Philippines Inc. launches Vetmedin S for canine heart disease, Vaxxitek HVT IBD ILT, Vaxxitek HVT IBD ND and Prevexxion RN for poultry diseases, and Entericolix for swine 

• Innovative products and new technology join hands in leading the fight against animal diseases.
• Boehringer Ingelheim Animal Health Philippines, Inc. releases new brands: Entericolix for swine, Vetmedin S for canine cardiac health, and for poultry, Prevexxion RN and new variants under the Vaxxitek brand: Vaxxitek HVT IBD ILT and Vaxxitek HVT IBD ND.

During the recent Philippine Veterinary Medical Association's 90th Scientific Conference and Annual Convention, Boehringer Ingelheim Animal Health Philippines, Inc. announced new brands, two cutting-edge farm equipment, and a brand-new educational website to local animal health care professionals. 

The SMX Convention Center in Pasay City hosted the event in February, which provided attendees with information about the most recent technological advancements and animal health knowledge. Boehringer Ingelheim Animal Health proceeded to introduce new devices and products that were of interest to the general public in accordance with the convention's theme, "Strengthening the Practice of Veterinary Medicine with Advanced Technologies and Networks."

“At Boehringer Ingelheim, we count on innovation as one of our core values. Fueled by our passion to improve the lives and well-being of humans and animals alike, our relentless pursuit of advancement delivered us these new products and devices. As innovative and as effective these products and tools may be, they can only serve their purpose with the help of every veterinary professional in this room and all over the Philippines. Boehringer Ingelheim reaches out to you. You are key in making the purpose of these products and tools come to life.Let us make these innovations work to make their benefits count in the lives of humans and animals here in the Philippines. Let us make these innovations work to make their benefits count in the lives of humans and animals here in the Philippines.” ~Dr. Sukje Sung, Head of Boehringer Ingelheim Animal Health Philippines, Inc. 

Dr. Sung gave an outline of the new variations of Vaxxitek for poultry and the three new brands for the three fundamental species the organization is presenting in the country: Entericolix for pigs, Prevexxion RN for poultry, and Vetmedin S for dogs with concerns about their cardiac health.

Prevexxion RN is effective against very virulent strains of Marek's disease, while Vaxxitek HVT IBD ILT and Vaxxitek HVT IBD ND help prevent Infectious Bursal Disease, Marek's Disease, Newcastle Disease, and Infectious Laryngotracheitis in poultry. Entericolix provides swine with 21 days of immunity against edema disease and diarrhea caused by E. coli and C. perfringens Type C; Additionally, Boehringer Ingelheim has introduced Vetmedin S, a medication that has been shown to improve the quality of life and delay the onset of congestive heart failure in dogs with heart disease.

Dr. Sukje Sung, Head of Boehringer Ingelheim Animal Health

Building up Dr. Sung was Dr. Melvin Cassion, Client Experience Lead for Boehringer Ingelheim Creature Wellbeing Philippines, Inc. "With regards to creature medical care, we are now past the period of therapy and control, that was so quite a while back. Prevention came next. However, Boehringer Ingelheim is now moving from disease prevention to prediction. He emphasized the resources available to the Philippine pork industry with that statement: SoundTalks®, a device that uses artificial intelligence in conjunction with always-on, in-barn audio monitoring to detect signs of respiratory disease, and FreVAXTM, an innovative vaccine injection device for pigs that does not require the use of a needle.

After that, Dr. Cassion unveiled the Animal Health Hub, an online learning portal that veterinarians can use to quickly access a variety of learning modules and keep up with the most recent technology and knowledge. The website, which initially launched with a focus on companion animals like dogs and cats, will soon include other species and be accessible to related users like veterinary students, farm managers, veterinary technicians, and others.

Learn more at www.boehringer-ingelheim.com.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.